Data Release of the AST3-2 Automatic Survey from Dome A, Antarctica

AST3-2 is the second of the three Antarctic Survey Telescopes, aimed at wide-field time-domain optical astronomy. It is located at Dome A, Antarctica, which is by many measures the best optical astronomy site on the Earth's surface. Here we present the data from the AST3-2 automatic survey in 2016 and the photometry results. The median 5$\sigma$ limiting magnitude in $i$-band is 17.8 mag and the light curve precision is 4 mmag for bright stars. The data release includes photometry for over 7~million stars, from which over 3,500 variable stars were detected, with 70 of them newly discovered. We classify these new variables into different types by combining their light curve features with stellar properties from surveys such as StarHorse.Comment: 16 pages, 20 figures, accepted for publication in MNRA

Exoplanets in the Antarctic Sky I. The first data release of AST3-II (CHESPA) and new found variables within the southern CVZ of TESS

Located at Dome A, the highest point of the Antarctic plateau, the Chinese Kunlun station is considered to be one of the best ground-based photometric sites because of its extremely cold, dry, and stable atmosphere. A target can be monitored from there for over 40 days without diurnal interruption during a polar winter. This makes Kunlun station a perfect site to search for short-period transiting exoplanets. Since 2008, an observatory has existed at Kunlun station, and three telescopes are working there. Using these telescopes, the AST3 project has been carried out over the last 6 yr with a search for transiting exoplanets as one of its key programs (CHESPA). In the austral winters of 2016 and 2017, a set of target fields in the southern continuous viewing zone (CVZ) of TESS were monitored by the AST3-II telescope. In this paper, we introduce the CHESPA and present the first data release containing photometry of 26,578 bright stars (m(i) <= 15). The best photometric precision at the optimum magnitude for the survey is around 2 mmag. To demonstrate the data quality, we also present a catalog of 221 variables with a brightness variation greater than 5 mmag from the 2016 data. Among these variables, 179 are newly identified periodic variables not listed in the AAVSO database (https://www.aavso.org/), and 67 are listed in the Candidate Target List. These variables will require careful attention to avoid false-positive signals when searching for transiting exoplanets. Dozens of new transiting exoplanet candidates will be released in a subsequent paper

Exoplanets in the Antarctic Sky. II. 116 Transiting Exoplanet Candidates Found by AST3-II (CHESPA) within the Southern CVZ of TESS

We report first results from the CHinese Exoplanet Searching Program from Antarctica (CHESPA)-a wide-field high-resolution photometric survey for transiting exoplanets carried out using telescopes of the AST3 (Antarctic Survey Telescopes times 3) project. There are now three telescopes (AST3-I, AST3-II, and CSTAR-II) operating at Dome A-the highest point on the Antarctic Plateau-in a fully automatic and remote mode to exploit the superb observing conditions of the site, and its long and uninterrupted polar nights. The search for transiting exoplanets is one of the key projects for AST3. During the austral winters of 2016 and 2017 we used the AST3-II telescope to survey a set of target fields near the southern ecliptic pole, falling within the continuous viewing zone of the TESS mission. The first data release of the 2016 data, including images, catalogs, and light curves of 26,578 bright stars (7.5 <= m(i) <= 15), was presented in Zhang et al. The best precision, as measured by the rms of the light curves at the optimum magnitude of the survey (m(i) = 10), is around 2 mmag. We detect 222 objects with plausible transit signals from these data, 116 of which are plausible transiting exoplanet candidates according to their stellar properties as given by the TESS Input Catalog, Gaia DR2, and TESS-HERMES spectroscopy. With the first data release from TESS expected in late 2018, this candidate list will be timely for improving the rejection of potential false-positives

Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke

Importance Dual antiplatelet therapy has been demonstrated to be superior to single antiplatelet in reducing recurrent stroke among patients with transient ischemic attack or minor stroke, but robust evidence for its effect in patients with mild to moderate ischemic stroke is lacking. Objective To evaluate whether dual antiplatelet therapy is superior to single antiplatelet among patients with mild to moderate ischemic stroke. Design, Setting, and Participants This was a multicenter, open-label, blinded end point, randomized clinical trial conducted at 66 hospitals in China from December 20, 2016, through August 9, 2022. The date of final follow-up was October 30, 2022. The analysis was reported on March 12, 2023. Of 3065 patients with ischemic stroke, 3000 patients with acute mild to moderate stroke within 48 hours of symptom onset were enrolled, after excluding 65 patients who did not meet eligibility criteria or had no randomization outcome. Interventions Within 48 hours after symptom onset, patients were randomly assigned to receive clopidogrel plus aspirin (n = 1541) or aspirin alone (n = 1459) in a 1:1 ratio. Main Outcomes and Measures The primary end point was early neurologic deterioration at 7 days, defined as an increase of 2 or more points in National Institutes of Health Stroke Scale (NIHSS) score, but not as a result of cerebral hemorrhage, compared with baseline. The superiority of clopidogrel plus aspirin to aspirin alone was assessed based on a modified intention-to-treat population, which included all randomized participants with at least 1 efficacy evaluation regardless of treatment allocation. Bleeding events were safety end points. Results Of the 3000 randomized patients, 1942 (64.6%) were men, the mean (SD) age was 65.9 (10.6) years, median (IQR) NIHSS score at admission was 5 (4-6), and 1830 (61.0%) had a stroke of undetermined cause. A total of 2915 patients were included in the modified intention-to-treat analysis. Early neurologic deterioration occurred in 72 of 1502 (4.8%) in the dual antiplatelet therapy group vs 95 of 1413 (6.7%) in the aspirin alone group (risk difference −1.9%; 95% CI, −3.6 to −0.2; P = .03). Similar bleeding events were found between 2 groups. Conclusions and Relevance Among Chinese patients with acute mild to moderate ischemic stroke, clopidogrel plus aspirin was superior to aspirin alone with regard to reducing early neurologic deterioration at 7 days with similar safety profile. These findings indicate that dual antiplatelet therapy may be a superior choice to aspirin alone in treating patients with acute mild to moderate stroke.Trial RegistrationClinicalTrials.gov Identifier: NCT0286900